All In Biotech

Drug Trial Radar · NCT05908786

A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma

A Phase Ib/II, Open-Label, Multicenter, Randomized Platform Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma (MORPHEUS-NEO HCC)

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

62

Actual

Start

Dec 5, 2023

Primary completion

Aug 27, 2025

Study completion Nov 13, 2025

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ib/II, open-label, multicenter, randomized platform study to evaluate neoadjuvant immunotherapy combinations in participants with resectable HCC. The study is designed with the flexibility to open new treatment arms as new agents become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the participant population.

Conditions

  • Carcinoma, Hepatocellular

Interventions

  • AtezolizumabDrug

    Atezolizumab will be administered at a dose of 1200 mg by IV infusion on Day 1.

  • BevacizumabDrug

    Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1.

  • TiragolumabDrug

    Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1.

  • TobemstomigDrug

    Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Pathologic Response (MPR) RateTime frame: At the time of surgery (up to 15 weeks)

Locations

14 sites in 6 countries. Site status is shown where the registry gives one.

  • University of Southern California (USC)

    Los Angeles, California

  • University of California Los Angeles (UCLA) - Cancer Care - Santa Monica

    Santa Monica, California

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Columbia University Medical Center

    New York, New York

  • UT Southwestern Medical Center

    Dallas, Texas

  • Klinikum Klagenfurt am Wörthersee

    Klagenfurt, Austria

  • Department of Internal Medicine III AKH and Medical University of Vienna

    Vienna, Austria

  • Centre Georges Francois Leclerc (CGFL)

    Dijon, France

  • Gustave Roussy

    Villejuif, France

  • University Essen

    Essen, Germany

  • Universitaets Klinikum Frankfurt - Zentrum der Inneren Medizin

    Frankfurt, Germany

  • Hospital Universitario Fundacion Jimenez Diaz.

    Madrid, Spain

  • Hospital Universitario Marques de Valdecilla

    Santander, Cantabria, Spain

  • Imperial College London - Imperial Centre for Translational and Experimental Medicine (ICTEM)

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.